In recent years, scientists discovered that an enzyme called CYP2D6 could possibly predict whether a patient would respond to the drug. Small studies aimed at confirming the predictive link, however, have been consistently inconsistent.
Adding Afinitor, an mTOR inhibitor, to tamoxifen helped women with metastatic breast cancer live about four months longer without their disease getting worse, according to a study presented Thursday at SABCS.
Every woman with a mutated BRCA1 or BRCA2 gene should have their ovaries removed to lower their risk of ovarian cancer, said Susan Domchek, MD, one of the educational sessions speakers at the 2010 SABCS.
Oncologists have begun trading in what had become a miracle pill for patients with chronic myeloid leukemia for more potent, newer-generation drugs that appear to work even better as first-line treatment for CML.
A new chemotherapy drug, called eribulin, extended survival by two and a half months in patients with locally recurrent or metastatic breast cancer whose cancers continued to progress despite treatment with numerous other drugs.
For metastatic melanoma patients who were out of treatment options, the immune system-targeted drug ipilimumab extended their lives by nearly four months compared with an investigational vaccine called gp100.